Antigenic polypeptide SE36 of malaria plasmodium, process for purification thereof, and vaccine and diagnostic agent using the antigen

Abstract

The present invention provides a polyeptide SE36 derived from the N-terminal domain (47 kd) of SERA (serine-repeat antigen) produced by malaria parasite, Plasonodium falciparum, at the erythrocyte stage, a process for purifing said polypeptide, and a malaria vaccine and diagnostic agent using as an active component said purified antigen obtained therefrom. SE36 can be produced in Escherichia coli on a large scale by deleting all or part of polymerized serines of the 47 kd serine-repeat region, whereby high purification is permitted. The human IgG3 antibodies spcically binding to SE36 prevents highly effectively growth of the protozoa in the red blood cells to inhibit fever and cerebral malaria, and further prevent the death.

1 - 15 . (canceled) 
     
     
         16 . A synthetic DNA fragment encoding a synthetic polypeptide consisting of the amino acid sequence of SEQ ID NO: 4, or a synthetic polypeptide which consists of the amino acid sequence of SEQ ID NO: 4 with a substitution, an addition or a deletion of amino acids the same as in the 47kd Serine Repeat Antigen (SERA) domain of  Plasmodium falciparum  HB3 strain, T9/96 strain, 3D7 strain, K1 strain, T9/102 strain, PA/7 strain or Camp strain,
 wherein the codon sequences of the synthetic polypeptide are converted in a form of  Escherichia coli  codon.